Nanomedicines and follow-on versions (also called nanosimilars in the EU) have been on the market partially for decades although without recognition of their nano properties in the beginning; a substantial number is in clinical development. Nanomedicines are typically synthetic and belong to the non-biological complex drugs. They show a high variability in form, structure, and size. Additionally large molecule biologics show nanocharacteristics meaning nano-dimension in size (1-100 nm) or specific properties related to these dimensions. The high complexity of nanomedicines with their heterogeneous structures do not allow a full physicochemical quality characterization, challenging the regulatory evaluation especially for follow-on versions upon comparison with the reference product. The generic paradigm with the sameness approach for quality and bioequivalence in blood plasma is not appropriate for nanomedicines where a similar approach is needed. After experiencing non-equivalence of authorized parenteral colloidal iron follow-on versions, EMA and FDA issued reflection papers and draft guidances for industry to present their current thinking on the evaluation of such complex products. A stepwise approach to evaluate the extent of similarity, from quality, including critical quality attributes (CQA) and assessment of nano properties, to a non-clinical biodistribution assay, required in the the EU but not in the US, and to clinical evaluation makes sense. The cumulated totality of evidence for the authorization of nanomedicine follow-on versions goes case-by-case. Interchangeability, or substitutability, is a challenge. However, a defined or even harmonized approval pathway for these follow-versions is still missing and causes potential differences in approval. To progress, a science-based discussion platform among stakeholders and experts in the field is necessary. An agenda has been agreed [5] , namely CQA assessment, publication of scientific and clinical findings, consensus on nomenclature and labelling, and regulatory actions on substandard complex drug products. Consensus created in a public private approach will support progress towards a defined and harmonized regulatory pathway for nanomedicines and their follow-on versions. This will provide drug innovation but also larger access to follow-on versions of nanomedicines, both a benefit for the patient.
Introduction
Advances in science and technology are the major drives for innovation in drug development to cover unmet therapeutic needs, to treat or prevent diseases, to improve the profile of therapeutics by better targeting body structures and tissues, and to increase quality, safety and efficiency of health care products. Apart from the innovation, access to comparable follow-on versions of such products for a larger population with reduced treatment cost, is a major purpose of the regulatory agencies aiming at patient' benefit (Hatch Waxman Act), which has also received priority by the FDA commissioner for amendments and comments according to a FDA meeting in June 2017 [1] .
Nanomedicines have the potential to overcome limits of former, differently manufactured and designed medicinal products. Nanomedicines cover a broad class of drugs with different complexity. Nanocrystals have been introduced to overcome specific water solubility problems of BCS class II -high permeability, low solubility -drugs in the biopharmaceutical classification system [2] . Active Pharmaceutical Ingredients (API) and mainly oral formulations to increase bioavailability or higher bioadhesion to membranes were addressed e.g. in ocular formulations. These nanocrystal formulations have given rise to an increasing number of submissions for regulatory approval [3] . A more complex nanomedicine class of medicinal product goes beyond formulation and uses nanomaterials to overcome tissue barriers (uptake) and to better target body sites for increased efficacy and safety. Such nanomedicines include liposomes, nanosuspensions, dendrimers, nanoparticular polymers and conjugates and others which are mostly applied parenterally; the whole nanomaterial product with its structures and composition, its specific manufacturing, defines the performance and characteristics, which contrasts the nanocrystal formulations with mainly the API considerations.
Nanomedicines have become a promising innovation priority for drug development opening new indications and treatment options for medicinal products. At the same time such nanomedicines authorized many years ago might have competition by follow-on versions if appropriate regulatory evaluation pathways existed. As these nanomedicines are highly complex products, and difficult to characterize, it is a challenge to have robust and consistent manufacturing processes in place, which define the product's profile and finally its quality, safety and efficacy. For nanocrystals, the main aspects to consider have been recently addressed in review from FDA authors summarizing the experiences from submissions over the last 35 years [3] . About a third of the nanomedicine submissions represent nanocrystals. As mentioned above such formulations show rather lower complexity compared to other nanomedicines with a different biodistribution and tissue targeting. Nevertheless, important issues like quality control of nanocrystal substances and products, their manufacturing and stability, are still challenging, like the nanoparticle size distribution, the impurities, or the correlation of in vitro-in vivo dissolution tests. These challenges have to be addressed with ongoing advances in science and technology. In addition, for the more complex nanomedicines major gaps still exist in understanding their mechanism of actions including the PK and the science behind. Therefore, the scientific and regulatory challenge of how to evaluate, define, and compare such products and their followon versions for authorization and good use in clinical practice, remains [4] .
The assessment of equivalence to a reference product for such complex drugs is difficult. The awareness of these challenges have grown among regulators, but there is still no defined or even harmonized regulatory evaluation pathways to assess follow-on versions of nanomedicines [5] . Importantly, the understanding of how to correctly use, interchange or substitute such medicinal products in daily practice and clinical routine is also mostly lacking in the health care professional community, as shown with hospital pharmacists active in the drug and therapeutic committees for drug selection and introduction of appropriate practical guidelines for the drug use [6, 7] .
The aim of this article consists of an update on the actual state and the current thinking of the regulators on the evaluation pathways for the drug authorization, especially for nanomedicine follow-on versions and their position in the landscape of the different drugs classes.
2. Important terms and definitions for the evaluation and authorization of drugs and their follow-on versions: the sameness and the similar approach
The term "nanomedicine" is applied to medicinal products which use nanomaterial and/or nanotechnology for their development and manufacturing [4] . Nevertheless, a uniformly accepted definition for nanomedicines still does not exist, the medicinal products vary largely in type and structure ( Fig. 1 [8] , b) and are used in a multitude of indications for acute and chronic diseases. A global technical definition applicable to all nanomedicines may not be feasible or useful. As a consequence, an early request for authority advice upon intended submission of such drug products is recommended [9] . The FDA recently drafted a guidance for industry for comment by March 2018 on drug products, including biological products, that contain nanomaterials [10] . This draft points to two important characteristics of these products, the dimension/size and the specific properties already given in the previous guidance from 2014 [11] . Both distinguish them from ordinary, non-nanomaterials or non-nanodrugs. Drug products containing nanomaterials are defined as:
1. a material or the end product which is engineered with at least one dimension or an internal or surface structure in the nanoscale range (approximately 1-100 nm) 2. a material or end product engineered to exhibit properties or phenomena including physical or chemical properties or biological effects that are attributable to its dimension(s), even if this dimension falls outside the nanoscale range up to 1 μm (1000 nm)
Nanomedicines have been used therapeutically for decades although, in the beginning not defined as such. In Fig. 2 some synthetic, non-biological nanomedicines are represented, indicating the existing and growing competition by follow-on versions, also called nanosimilars e.g. in the EU [13] , a term not used by the FDA; over 50 nanomedicines are in clinical development. An overview of the existing pathways for the FDA and the EMA to evaluate and authorize follow-on versions of drugs is depicted in Fig. 3 . The regulatory challenges, lacking awareness, but also absence of harmonization were mirrored by differences in the authorization of nanomedicine follow-on versions. Upon the authorization of colloidal i.v. iron sucrose similar solutions in some European countries in the early 2000, the inadequate equivalence of the similar versions authorized according to article 10(1) for generics ( Fig. 3b) was only revealed by clinical efficacy studies after approval [14, 15] . The generic sameness approach is not valid for these parenteral nanomedicine follow-versions, which belong to the group of synthetic, non-biological complex drugs (NBCDs) (Fig. 4 [16] ).
NBCDs consist of different closely related and often nanoparticulate structures that cannot be fully quantitated and characterized by physicochemical analytical means. A well-controlled robust manufacturing process is fundamental to ensure quality, safety and efficacy [17] . Examples include glatiramoids, iron-carbohydrate complexes, polymeric micelles, complex ocular emulsions and liposomes.
Synthetic nanomedicines are NBCDs but not reciprocally. A careful distinction of NBCDs with potential subclasses like the iron nanocolloidals have to be defined to better and more precisely address their regulatory evaluation. For follow-on versions of synthetic large molecule drug products the "similar" instead of the "sameness" approach is most challenging and new for the agencies. The experience and growing awareness on these nanomedicine follow-on versions resulted in a high restriction or even denial of authorization by western authorities. Furthermore, it initiated also research activities to explore a Selection of nanomedicines [8] b Size comparison of nanomedicines the underlying science [18] . This NBCD/nanosimilar experience contrasts with the biosimilar one, where the regulatory approach was successfully defined, elaborated, and introduced by the EMA more than a decade ago and before follow-on versions were submitted to the authorities; since then the FDA has also accepted this approach (Fig. 3a) . Valuable information for health care professional on biosimilars, including a glossary, has been issued by the EMA explaining why a similar approach for structure, biological activity and efficacy, safety, and immunogenicity profile is necessary and appropriate for these large molecule biologics with a natural variability [19] . Such biologics, e.g. mAB, may also be 'nanomedicines' depending on their size and structure (see Fig. 1b ) and are also addressed in the recent FDA draft [10] , which will be discussed below. In any case, synthetic nanomedicines cannot be regarded as biologics as they are not products of biological source and therefore separate from them. It is important to note that in the US, biologics lie legally outside the Food, Drug and Cosmetics Act and are authorized under Public Health Service Act (Fig. 3a) .
Biologics together with the NBCDs represent the class of complex drugs (Fig. 4) . In contrast to small molecule, well-defined, drug products, these complex drugs represent highly complicated and heterogeneous structures, defined and created by a robust, although complicated, manufacturing process; they cannot be characterized fully by in vitro physicochemical means. The assessment of yet unknown critical quality attributes (CQA) [20] makes the comparability or the in vitro evaluation of equivalence of such products almost impossible and renders the classical generic approach invalid, as pharmaceutical equivalence and bioequivalence are necessary to prove therapeutic equivalence.
A CQA addresses a physical, chemical, biological, or microbiological property or characteristic that should be in an appropriate limit, range, or distribution to ensure the desired product quality. Therefore and to show the necessary similarity, the equivalence evaluation of follow-on versions needs a totality of evidence approach [21, 22] (Fig. 5 [23] ). such "non-protein" complex drugs, the nonprofit public-private partnership working group on NBCDs (NBCD WG) was created in 2009. The NBCD WG offers a platform among stakeholders to create awareness, to discuss and support, science-based, the introduction of a so far lacking appropriate and harmonized regulatory pathway for the evaluation of these medicinal products [24] . The NBCD WG's ultimate mission is to ensure that appropriate and harmonised sciencebased approval and post-approval standards for NBCDs are introduced globally, for patient safety and benefit. The NBCD WG, composed of experts on NBCDs from academia, companies, and institutions, gives input by documenting, presenting, and promoting regulatory sciences. The group is accessible for stakeholders to exchange and contribute to the progress in the field. They constantly publish articles in peer-reviewed journals, show active presence in important scientific and professional societies, and collaborate with institutions and experts. Also the term "NBCDs" was created and brought into the involved communities together with other important definitions [25] to finally contribute to a regulatory and scientific landscape of drugs with their existing challenges (Fig. 6 ). The NBCD WG was also involved in the creation of the first published handbook as a reference on NBCDs [17] . Educational initiatives to improve correct use and handling of nanomedicines for health care professionals are ongoing [6, 7] together with periodical exchanges with regulators and knowledgeable institutions [5] . The equivalence questions for quality evaluation (Pharmaceutical Equivalence, PE), biodistribution (Bioequivalence, BE), to finally Therapeutic Equivalence (TE) is challenged heavily by the nanomedicines and their similars. Published documents in form of reflections (EMA) or drafts for comment (FDA) facilitate exchange and discussion to create progress. As an example related to nanomedicine follow-on versions, the EMA published a reflection paper on non-clinical studies for generic nanoparticle iron medicinal product application [26] and on data requirement for intravenous iron-based nanocolloidal products developed with reference to an innovator medicinal product [27] . In the US the FDA draft guidance for industry on nanomaterial containing drugs [10] and the Governmental Account Office (GAO) report with a focus on NBCDs [29] made public in 2018 will be addressed in the next section.
3. Nanomedicines and NBCDs: recent regulatory reflections and guidance drafts towards defined and harmonized regulatory approaches?
Parenteral iron colloidals have been widely used for many years in a broad variety of iron oxide carbohydrates medicinal products. Some competing follow-on versions (nanosimiliars) are on the market in certain geographic regions (Fig. 2) , although lack of therapeutic equivalence ( [14, 15] , see above), but also safety issues [30] have been observed, because inappropriate authorization pathways were used. The complexity of these intravenous iron nanoparticle drugs has challenged the established regulatory methods to assess quality, safety and efficacy and shows that nanomedicines have to be addressed differently for their evaluation [31] . A weight of evidence approach from quality, to non-clinical, and finally clinical data is needed. In the EMA reflection paper, the evaluation of nanoparticle iron medicinal products in a rodent model was proposed to elucidate the pharmacokinetics and more specifically to compare the non-clinical biodistribution data for the bioequivalence evaluation of colloidal iron follow-on versions [26] . Such products cannot be characterized by quality means alone, as uncertainties about important CQA for the in vivo performance exist. Therefore, according to the EMA, a validated non-clinical evaluation will add valuable comparability data in a stepwise approach (Fig. 7) . As a simple extrapolation from animal data to human is not possible, the nonclinical data are required in addition to conventional human bioequivalence or PK data and they do not exclude further clinical studies to guarantee quality, safety, efficacy comparability of the iron nanomedicine Fig. 6 . The illustrative complex drug landscape [5] . Fig. 7 . EMA: The stepwise comparability approach for nanosimiliars (according to [27] ). [27] . Biomarkers in clinical data are useful as classical concentration measurements of the drug product or of the iron released to the targeted tissues, but they are technically not feasible and the scientific understanding of detailed PK and PD mechanisms is still incomplete. There are published investigations with this rat model comparing iron sucrose originator versus follow-on versions (also called iron sucrose similiars or ISSs) from different regions of the world, but also comparing different iron carbohydrate complexes [32] [33] [34] . In a very recent publication an alternative avian model for non-clinical evaluation was presented as able to differentiate nanoparticular iron complex drugs by their tissue disposition in the turkey embryo [35] . An MRI assay as a noninvasive method for iron disposition in rats was just published [36] .
In contrast to the EU, the FDA does not rely on non-clinical evaluation for such nanoparticle drugs as the animal data do not necessarily predict human disposition. However, they do agree that the accurate measure of tissue distribution in humans is technically difficult, but instead argue that physicochemical characterization together with plasma pharmacokinetics are more sensitive in detecting subtle differences or in showing sameness between two iron colloidal formulations than clinical efficacy and safety studies. Therefore, extended physicochemical quality assessments on potential follow-versions of such iron nanocolloidals have to be used, e.g. to compare particle size distribution, the polynuclear iron core, and the carbohydrate shell together with appropriate statistical analysis. Accordingly, sufficient sameness should be demonstrated and also batch to batch consistency could be guaranteed [37] . This strengthening of analytical assessments can be understood from the complex drug development process (Fig. 5 ). This approach is also applied to prove high similarity to a reference product for biosimilars. As with biosimilars [38] the assessment of the development process including the characterization of the pharmaceutical quality together with PK/PD confirmation was strengthened compared to the clinical trials. The partly different approach to evaluate and compare nanocolloidals in the US and the EU indicates the importance for exchange and discussion among the stakeholders as indicated above, to progress in the regulatory approach for nanomedicine follow-on versions [5, 24] .
The recently published FDA draft guidance on drug products containing nanomaterials [10] was open for comments untill March 19, 2018. The draft addresses both synthetic drug products and biologics containing nanomaterials and has therefore a broad scope. This guidance draft can be linked to two other documents, namely the Guidance for Industry considering whether an FDA-regulated product involves the application of nanotechnology [39] and the GAO report on the FDA's approach to assess generic versions of NBCDs as nanomedicine follow-on versions [29] . The later report is also open to comments. One has to be aware that the FDA does not officially accept the NBCD term, although it is often used in presentations or publications, as it is an accepted term in other regions of the world. As mentioned above and according to the Hatch Waxman Act, the FDA has to support access to medicines by follow-on versions; this is also a key aspect of the two documents. The guidance draft for industry on drug products containing nanomaterials dwells into definitions and terms related to nanomedicines which is important and adds to a common language (see above the definition of nanoproducts). By March 30, 2018 , the deadline for submitting comments, 12 had been posted [40] . Most comments agree that the provided draft presents an overarching document which has to be followed by more specific guidance for individual products, as some draft guidance documents for ANDA submissions of nanomaterials already exist. The draft guidance states the importance of adequate characterization of the nanomaterials together with understanding how the nano-attributes affect quality, safety, and efficacy. On the other hand, evidence showing the extend to which these attributes have an impact on patients, are rare. Therefore, the document has more of a white paper character, covering physicochemical characterization, therapeutic application or routes of administration with applicability limits, rather than a guidance directing and assisting a potential developer/manufacturer of nanomedicines [38] , comments from the NBCD WG (FDA-2017-D-0759-004) and from the Nanomedicine Alliance (FDA-2017-D-0759-005) ]. The Vifor Pharma comment (FDA-2017-D-0759-003) focuses on the non-appropriateness of the existing ANDA pathway to evaluate NBCDs and nanomedicine follow-on versions and proposes to apply a stepwise approach as mentioned above (Fig. 7) . The listed factors for assessment of nanomaterials, including CQA, are well compiled (Table 1) , but again the science behind is still limited. Interestingly and in contrast to the above addressed FDA publication on iron nanoparticle [37] , animal studies are also listed. Another comment addresses the difficulty in putting the draft in context with existing FDA guidelines, such as the one on nanotechnology [39] ; neither the considerations for FDA-regulated products involving nanotechnology, nor the current understanding of the role and importance of the nano-dimension of nanomedicines have been addressed. Further documents on nanomedicines have to be issued. There is still the need for the stakeholders to exchange, publish, and discuss progress and next steps, in order to benefit from the existing expertise to better define the appropriate next regulatory approval steps for nanomedicines and their follow-on versions.
The GAO report was triggered by a congress requirement, H.R. 1576, in March 2015 to assess the FDA's current regulatory pathway for reviewing generic versions of NBCDs. The bill was transferred to the Committee on Energy and Commerce, which mandated the Governmental Accountability Office (GAO) to give a report within two years to the Congress. This report was made public in January 2018. The recommendation to the FDA consists of making public its plan to issue and revise guidance on NBCDs. The report was based on a thorough literature search analysis to identify scientific challenges, when evaluating generic NBCDs. This also resulted in a list of NBCDs on the US market. Furthermore, it identified and evaluated the steps the FDA has undertaken to address these challenges. Interviews with different stakeholders took place, among them as indicated in the report the NBCD WG. The US list of NBCDs includes 28 products (annex 1 of the report) revealing also that most NBCDs are nanomedicines:
9 liposomal drugs; 9 nanoparticle drugs: 7 iron nanocolloidals including 1 MRI diagnostic, sevelamer; 5 stabilized (nano/micro) products: albumine-stabilized paclitaxel, nano-or microemulsified propofol, estradiol, cyclosporine, lidocaine/ prilocain, amphotericin B lipid complex 3 low molecular heparins to prevent blood clotting -in the EU considered as biologics -, 2 others: 1 nanocrystal product (paliperidone palmitate), 1 synthetic polypeptide (glatiramer)
The GAO report addresses the FDA and the Center for Drug Evaluation and Research (CDER) which are legally bound by the Food, Drug and Cosmetic Act and the ANDA procedure for generics; to some extent Table 1 Factors for assessment of nanomaterials [10] .
1. Adequacy of characterization of the material structure and its function. 2. Complexity of the material structure. 3. Understanding of the mechanism by which the physicochemical properties of the material impact its biological effects (e.g., effect of particle size on pharmacokinetic parameters). 4. Understanding the in vivo release mechanism based on the material physicochemical properties. 5. Predictability of in vivo release based upon established in vitro release methods. 6. Physical and chemical stability. 7. Maturity of the nanotechnology (including manufacturing and analytical methods). 8. Potential impact of manufacturing changes, including in-process controls and the robustness of the control strategy on critical quality attributes of the drug product. 9. Physical state of the material upon administration. 10. Route of administration. 11. Dissolution, bioavailability, distribution, biodegradation, accumulation and their predictability based on physicochemical parameters and animal studies.
the 505(b)(2) pathway could be used for NBCD/nanosimilar follow-on versions (Fig. 3a) . As 505(b)(2) is within the NDA part, the intended broader drug access is then limited by the impossible substitution or interchange with an originator drug product. Additional limitations exist due to the lack of full characterization of NBCDs/nanomedicines, by pharmaceutical quality assessment (CQA!), and the restricted understanding of the exact mechanism of action. Therefore, a "similar approach" like a modified 351(k) pathway would be a good option for these highly complex drug products (Figs. 1-3) . As NBCDs/-follow-on
versions cannot be a biologic by definition, the biosimilar approach is not possible. In addition, in the US a legal change by the congress would be necessary, as biosimilars are licensed under the Public Health Service Act. Nevertheless, to benefit from the existing experience with biologics, the remaining NBCD/-follow-on versions, should be evaluated by a "similar approach" (Fig. 4) . Such an approach would also overcome existing hurdles with nanosimilars in Europe and in the rest of the world (Fig. 8) . astonishing and different outcomes regarding authorizations of followon versions of complex drugs between the US (FDA) and the EU (EMA), calling for harmonization as little evidence is brought into the public domain [41] . Low molecular weight heparins follow-on versions are not considered biologics in the US but in the EU they are seen as biosimilars (see above). A doxorubicin liposomal follow-on version of Doxil™ received market authorization as Lipodox™ in the US and failed to do so in the EU. The most recent case of a nanomedicine follow-on version authorized, was glatiramer acetate, a synthetic co-polymer of amino acids, classified as a polypeptide by the FDA. The originator Copaxone™ was approved for multiple sclerosis treatment by the FDA in 1996. The follow-on versions received a market access as Glatopa™ in the US in 2015, and as Remurel® in the EU (Fig. 2) . The FDA established equivalence between Glatopa™ and Copaxone™ across four major criteria: starting material and basic chemistry, structural signatures of the chemical synthesis processes (polymerization, depolymerization, purification), physicochemical properties (analytics) and biological and immunological properties using orthogonal assays [42] . They approved a generic version mainly based on an in-depth quality characterization. In contrast, Remurel®, approved in 2017, was evaluated for safety and efficacy in a multicenter phase 3 trial (large scale, randomized, double-blind, placebo-controlled) [43] . The clinical results for efficacy and safety comparing the originator with the generic glatiramer were in the predefined equivalence margins and showed similarity of the products. This shows that there were different and not comparable pathways used to assess nanomedicine follow-on versions by the FDA and the EMA; the one showing comparable sameness in physicochemical and biological characterization including CQA, the other using a clinical similarity approach although being approved as a generic! It will be interesting to see how the FDA will now evaluate Remure l ® with its data upon the filed submission. These examples demonstrate very well that the authorization pathway for nanomedicines as a similar or generic approach is still under debate. No identical (harmonized) procedure is defined between the two important agencies in the US and the EU.
Conclusions and how to progress?
Submissions of nanomedicines to the agencies is reality and relevant with increasing importance as published by the FDA (Fig. 9 [44] ). Nanomedicines and more specifically their follow-on versions have challenged the existing regulatory evaluations for market access. Nanomedicine follow-on versions have partially been authorized based on the generic paradigm for fully defined small molecule drugs as specific properties of complex colloidal drugs and the related manufacturing processes were not realized or even unknown (Fig. 4) . Eventually, important safety and efficacy equivalence problems occurred after market approval. This triggered reflection papers (EMA) and draft industry guides (FDA) for selected products like the parenteral iron carbohydrates representing nanoparticular drugs. The EMA and the FDA have different pathways for the approval of generics. In contrast to the EU, where substitution and interchange with "generics" remains in the responsibility of the national authorities, the FDA decides upon the authorization for the US market; how to use follow-on versions as competitors, alternatives or substitutes of a reference originator. The challenge for complex drugs and the evaluation of their follow-on versions is to demonstrate sufficient similarity. The decision has to be based on a totality of evidence evaluation using a more appropriate stepwise procedure (Fig. 7) ; for the manufacturer or developer an early advice from the regulators for the required data is recommended. For a common understanding among different authorities and to progress finally also to harmonized procedures, a science-based exchange on the current thinking, publications of findings and experiences, presence in public scientific and professional meetings but also more informal discussion among the stakeholders are helpful or necessary for progress. A special issue of the Annal of the N Y Academy of Science was dedicated to the equivalence of complex drug products: scientific and regulatory challenges. It was published in 2017 and includes reviews and original reports around biotechnology-and nanotechnology-driven complex drugs and their follow-on versions. Authors from different agencies, knowledgeable institutes, originator and generic companies including Fig. 9 . Number of drug submissions containing nanomaterials to CDER/FDA [44] . the members of the steering committee of the NBCD WG contributed. The leading article on equivalence advances and challenges [5] also provides an agreed agenda on the most important next steps for progress:
1. Assessment of CQA to establish equivalence for follow-on versions 2. Need to publish scientific but also clinical findings in the public domain for further progress 3. Necessity to develop consensus for nomenclature and labelling of these complex products 4. Regulatory actions when substandard complex drug product are identified
Answering these questions will advance regulation and counteract the challenges. The landscape of drugs driven by the complexity of pharmaceutical equivalence and bioequivalence (Fig. 6 ) could then be finetuned to define more precisely the data requirements. Progress would also overcome the actual case-by-case approach which results sometimes in different or even contradictory authorizations, difficult to change after approval (see above). As a consequence, a public-private partnership could partially be created to achieve the goal of the Hatch Waxman Act: keep innovation high but also give access to a broad population for effective and safe drugs to affordable prices. This applies particularly to the nanomedicines and their follow-on versions. The goal is to exploit achievements from the basic science (bench) and to bring them to the patient (bed) by evolving the regulatory sciences. It also includes the necessary knowledge transfer to and education of the users on such innovations and the place of their follow-on versions in clinical practice. Such an approach will also mean maximum benefit for patients.
